APA (7th ed.) Citation

T, M., S, A., LJ, J., A, A., E, N., MD, B., & TJ, K. (2022). Cladribine Treatment for MS Preserves the Differentiative Capacity of Subsequently Generated Monocytes, Whereas Its Administration In Vitro Acutely Influences Monocyte Differentiation but Not Microglial Activation. Frontiers in immunology, 13, 678817. https://doi.org/10.3389/fimmu.2022.678817

Chicago Style (17th ed.) Citation

T, Medeiros-Furquim, Ayoub S, Johnson LJ, Aprico A, Nwoke E, Binder MD, and Kilpatrick TJ. "Cladribine Treatment for MS Preserves the Differentiative Capacity of Subsequently Generated Monocytes, Whereas Its Administration In Vitro Acutely Influences Monocyte Differentiation but Not Microglial Activation." Frontiers in Immunology 13 (2022): 678817. https://doi.org/10.3389/fimmu.2022.678817.

MLA (9th ed.) Citation

T, Medeiros-Furquim, et al. "Cladribine Treatment for MS Preserves the Differentiative Capacity of Subsequently Generated Monocytes, Whereas Its Administration In Vitro Acutely Influences Monocyte Differentiation but Not Microglial Activation." Frontiers in Immunology, vol. 13, 2022, p. 678817, https://doi.org/10.3389/fimmu.2022.678817.